10-Q: bioAffinity Technologies Reports First Quarter 2024 Results, Revenue Increases Significantly Following Acquisition

bioAffinity Technologies' first quarter 2024 results show a significant increase in revenue due to the acquisition of Precision Pathology Laboratory Services, but the company continues to operate at a loss.

Summary

• bioAffinity Technologies reported a net loss of $1.96 million for the first quarter of 2024, compared to a net loss of $1.53 million for the same period in 2023.
• The company's revenue increased significantly to $2.41 million in Q1 2024, up from $921 in Q1 2023, primarily due to the acquisition of Precision Pathology Laboratory Services (PPLS).
• Operating expenses also increased to $4.35 million in Q1 2024 from $1.56 million in Q1 2023, driven by the inclusion of PPLS's operating costs.
• The company's cash and cash equivalents were $2.45 million as of March 31, 2024, down from $2.82 million at the end of 2023.
• bioAffinity Technologies raised $2.05 million in net proceeds from a direct offering of common stock in March 2024.
• The company has an accumulated deficit of $46.6 million as of March 31, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional funding.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue has increased significantly due to the acquisition, the company's continued losses, going concern warning, and need for additional capital raise concerns. The sentiment is therefore negative overall.

Positives

• The acquisition of PPLS has significantly increased revenue, with patient service fees contributing the most.
• The company successfully raised $2.05 million through a direct offering of common stock.
• The company is actively working to expand commercialization efforts for its CyPath Lung test.
• The company has made progress in developing its diagnostic tests and therapeutic products.

Negatives

• The company continues to operate at a loss, with a net loss of $1.96 million in Q1 2024.
• Operating expenses have increased significantly due to the acquisition of PPLS.
• The company has an accumulated deficit of $46.6 million.
• Management has expressed substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company's cash reserves have decreased from $2.82 million at the end of 2023 to $2.45 million as of March 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company may be forced to curtail operations, delay clinical trials, or cease operations if it cannot secure additional funding.
• The company's diagnostic tests and therapeutic products are still in development and may not be successful.
• The company faces competition from other therapies and diagnostic tests.
• The company's financial results are subject to various risks and uncertainties, including economic and political instability.

Future Outlook

The company expects to continue to incur significant operating losses for the foreseeable future as it continues the development of its diagnostic tests and advances them through clinical trials. The company anticipates raising additional cash through the private or public sales of equity or debt securities, collaborative arrangements, or a combination thereof to continue to fund its operations and develop its products.

Management Comments

• Management concludes that there is substantial doubt about the company's ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying condensed consolidated financial statements.
• Management believes that the company needs to raise further capital through the sale of additional equity or debt securities or other debt instruments, strategic relationships or grants, or through exercised outstanding warrants to support its future operations unless its revenue increases significantly.

Industry Context

The company operates in the biotechnology and diagnostics industry, focusing on early cancer detection and therapeutic development. The increase in revenue is a positive sign, but the company's financial position remains precarious. The company's success depends on its ability to commercialize its products and secure additional funding.

Comparison to Industry Standards

• bioAffinity's revenue growth is notable compared to other early-stage biotech companies, primarily due to the acquisition of PPLS.
• However, the company's continued losses and going concern warning are not uncommon for companies in this stage of development.
• Other companies in the diagnostic space, such as Exact Sciences and Guardant Health, have also experienced significant losses while scaling their operations.
• bioAffinity's reliance on capital raises is typical for biotech companies, but the company's current cash position is a concern.
• The company's success will depend on its ability to achieve regulatory approvals and commercialize its products effectively, similar to other companies in the industry.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment if the company cannot secure additional funding.
• Employees may be impacted by potential layoffs or restructuring if the company's financial situation does not improve.
• Customers may be affected by potential delays or disruptions in the availability of the company's diagnostic tests.
• Suppliers and creditors may face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company will seek stockholder approval for the issuance of shares upon exercise of warrants at the Annual Meeting of Stockholders on June 4, 2024.
• The company will continue to pursue commercialization of its CyPath Lung test.
• The company will continue to seek additional funding to support its operations and research and development programs.

Key Dates

Keywords

bioAffinity Technologies, CyPath Lung, Precision Pathology Laboratory Services, diagnostic tests, lung cancer, financial results, revenue, operating expenses, net loss, capital raise, going concern, clinical trials, therapeutic products